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Neutrophil extracellular DNA traps (NETs) are DNA scaffolding structures released by 
neutrophils in response to injury, stress and infection and have been implicated in cancer 
metastasis. We sought to determine if NETs are detectable in the plasma of patients with 
muscle-invasive bladder cancer before, during, and after radical cystectomy (RC). We also 
explored whether higher NET levels are associated with infection and early recurrence, and if 






In a pilot randomized clinical trial, 29 men consumed nutrition supplementation 5 days 
before and 5 days after radical cystectomy at Kansas Health System. The intervention group 
(n=14) took a SIM beverage containing L-arginine (Nestlé, Impact Advanced Recovery®). 
The control group (n=15) also received oral nutrition support (Nestlé, Boost Plus®). Blood 
samples were collected at baseline, intra-operatively, and post-operative days 2, 14, and 30. 
Neutrophil elastase was measured using sandwich ELISA analysis. Granulocyte-colony 
stimulating factor (G-CSF) and plasma IL-6 were measured using MILLIPLEX® map human 
cytokine kit 1. High sensitivity C-reactive protein (hs-CRP) was measured at Quest Labs. 





Twenty-six of the 29 patients had enough plasma to evaluate for NETs. All samples 
analyzed had detectable levels of NETs. There were no significant differences between NET 
levels in those with clinically identified infection or 3-year cancer recurrence. G-CSF was 
significantly different between the intervention and the control groups from baseline to POD2 
and surgery to POD2. There were no significant correlations between NETs and IL-6 or NETs 
and hs-CRP. We did not detect a significant difference in NETs between the intervention and 






In our study, NETs were detectable in patients with bladder cancer. NET levels were 
highly variable across participants at all time points. G-CSF was significantly higher in the 
intervention group intraoperatively. NET levels did not differ between patients receiving the 
SIM drink as compared to those receiving the control nutrition supplement. Future research 
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CHAPTER 1: Introduction 
 
Bladder cancer accounts for 7% of all new cancer cases and approximately 12,520 deaths 
in the United States annually making it the fourth most common cancer diagnosis in men in 2018 
(1). The American Society of Clinical Oncology (ASCO) treatment guideline identifies radical 
cystectomy (RC) as the gold standard treatment for muscle-invasive bladder cancer (2). 
Following RC, approximately 34% of patients experience cancer recurrence and metastasis (3). 
The gold standard treatment for this cancer type is the most efficient at sparing lives, but has a 
25% post-operative infection rate (4) that is associated with the high rate of cancer recurrence. 
While there is a hypothesized connection between post-operative infection following RC and 
cancer recurrence, the mechanisms are not fully understood. Neutrophil extracellular DNA traps 
(NETs) are DNA scaffolding structures released by neutrophils in response to injury, stress and 
infection and have been found to promote cancer metastasis in cancers of the liver, pancreas, and 
lung (5-7).  While NETs have been implicated in cancer metastasis, it is unknown whether NETs 
are induced by RC. 
 
NETs are formed by neutrophils via the innate immune system to trap microbes that 
cause infection. Recent research has found this ‘trapping’ promotes tumor cell invasion into 
healthy tissue when NETs form following surgical stress (8). Immune cells and trapped cancer 
cells secrete inflammatory cytokines that mobilize neutrophils and stimulate NET formation, 
thus a higher number of measured NETs is hypothesized to be associated with cancer metastasis 
(7). If NETs are detectable in human plasma, measuring the number of NETs perioperatively 
may be a prognostic tool for immune defense and/or cancer recurrence. Though it is unknown 
whether NETs are induced by RC, the high rate of post-operative infection in this population
2  
provides an opportunity to investigate the potential for utilizing NETs as a prognostic tool and 




Pilot studies have investigated specialized immunonutrition (SIM) aimed to fulfill 
nutrient insufficiencies prior to RC and were found to reduce post-operative urinary tract 
infection, paralytic ileum, and index scores according to field-wide accepted Clavien grades (9, 
10). NETs are not well understood, but it is known that NETs form in the presence of 
inflammation and infection. If SIM drinks reduce post-operative infection, it is possible that their 
mechanism also includes a reduction of plasma NETs. A nutrition intervention aimed to 
prophylactically reduce postoperative infection rates may also reduce subsequent NET 
formation. It is important to identify if NETs are induced by RC and whether NETs are 




Statement of Purpose: To investigate whether NETs are associated with infection or cancer 






1.   Are NETs detectable in the plasma of surgical oncology cystectomy patients? 
 
2.   Are higher NET levels associated with infections or 3-year recurrence rate in patients 
following RC? 
3.   Does perioperative SIM influence the formation of NETs compared to a perioperative 
nutrition control group?
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CHAPTER 2: Review of the Literature 
 
Introduction to Bladder Cancer 
 
Bladder cancer is the fourth most diagnosed form of cancer in men in the United States 
and is generally diagnosed in an early stage of disease. This cancer accounts for 7% of all new 
cancer cases for males in the US (1). Bladder cancer is broadly categorized by whether the 
tumor is non-muscle- invasive or muscle-invasive. Non-muscle-invasive bladder tumors are 
found in the shallow layers of epithelial bladder tissue whereas muscle-invasive bladder tumors 
also invade deeper layers of muscle tissue (1). Approximately half of newly diagnosed cases 
are stage 1, non- muscle-invasive (1). The five-year survival rate for Stage I bladder cancer is 
88%, but drops to only 46% for those with a Stage III diagnosis (1). The five-year survival rate 
for metastasized bladder cancer, or Stage IV, is 15% (1). Although most cases are diagnosed in 
early stages, bladder cancer has a high recurrence rate. There is a need for investigation into 





The gold standard treatment for muscle-invasive bladder cancer or high-risk non-muscle- 
invasive forms is radical cystectomy (RC), removal of the bladder, urinary diversion, and 
resection of intestinal tissue for urinary tract reconstruction (2). A post-operative infection rate of 
25% is observed for bladder cancer patients who have undergone RC (4). The highest rate of 
recurrence is found in those patients who undergo RC (3). While there is a hypothesized 
connection between post-operative infection following RC and cancer recurrence, the 
mechanisms are not yet fully understood. Researchers are looking to identify these mechanisms 
in an effort to prevent post-operative infection and lower recurrence rate following RC.
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Population affected by bladder cancer and Treatment through RC 
 
Bladder cancer affects older adults, 9 out of 10 diagnoses are adults aged 55 years or 
older (1). Men have a 4 to 1 higher likelihood of developing bladder cancer than women and 
white Americans are twice as likely to develop bladder cancer as African Americans or Hispanic 
Americans (1). The biggest risk factor for development of bladder cancer is tobacco use; half of 
all diagnosed individuals have used or currently use tobacco (1). Another risk factor associated 
with disease development is exposure to industrial chemicals that include aromatic amines (1). 
The most commonly identified professions of those diagnosed are hair dressers, truck drivers, 
machinists, painters, and those who work in the leather industry (1). An association between 
daily fluid intake and bladder cancer has been suggested, which is thought to dilute carcinogen 
exposure to the bladder tissue (11). It is hypothesized that voiding the bladder of urine more 




Approximately 25% of patients diagnosed with bladder cancer are treated with RC (12). 
Due to the high rate of metastasis, surrounding organs are also typically removed during this 
surgery (12). RC for male patients includes removal of the bladder, prostate, surrounding lymph 
nodes, and seminal vesicles (12). RC for female patients includes removal of the bladder, 
fallopian tube(s), ovaries, uterus, vaginal tissue, and surrounding lymph nodes (12). Following 
the removal of these tissues, the urinary tract is rebuilt using segments of intestinal tissue. 
Intestinal tissue is rich in bacteria, which may play a role in the high rate of post-operative 
infection (4). Prophylactic antibiotics are used in an effort to stave off post-operative infection 
following RC (12).
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RC is carried out using either an open surgical method or a laparoscopic method. Open 
surgery includes a broad incision from the naval to the pelvis while the laparoscopic surgery 
includes an average of six small incisions (12). Both surgeries take between 6-8 hours and data 
show a positive correlation between surgical procedure duration and post-operative infection in 
both regardless of surgical approach (4).  Parker et al. reported a significant increase in post- 
operative infection in cystectomy surgeries lasting longer than 480 minutes or those individuals 
who require a peri-operative blood transfusion, which tends to be associated with a longer 




Complications in treatment 
 
Participants who receive RC are prone to many serious complications. Surgeons utilize 
portions of the intestine to reconnect the urinary tract, therefore connecting two sets of tissue that 
innately contain a large number of bacteria (4). Parker et al. found that approximately 25% of 
individuals who receive RC are diagnosed with an infection within 30 days (median = 13 days) 
(4). When Shabsigh et al. followed RC recipients for 90 days post-operatively, 64% experienced 





Recurrence within 5 years following RC is approximately 34% (3, 13). Between 35-50% 
 
of patients who undergo RC experience cancer recurrence at some point in life (3, 4, 6, 10, 11, 
 
13). Identifying the mechanisms through which recurrence and metastasis occur in surgical 
cancer therapies is important to improve treatment outcomes.
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Introduction to neutrophil extracellular DNA traps (NETs) 
 
Neutrophils are the innate immune system’s first line of defense and recent studies have 
identified a DNA scaffolding structure built by these leukocytes that may promote cancer 
metastasis, especially in the presence of postoperative inflammation and/or infection (5-8). These 
scaffolding structures, or NETs, are produced by neutrophils in the presence of stress (ischemia, 
surgical stress, infection, etc.) through the ejection of their own DNA-containing chromatin near 




The biochemical mechanism of forming NETs is commonly referred to as NETosis. This 
form of programmed cell death is vaguely understood and is at the forefront of immunological 
research. This cell death is characterized by decondensation of chromatin, the dissolving and 
disintegration of both the nuclear and cellular membranes, (14) and the ejection of chromatin 
into the extracellular matrix. NETosis is stimulated by a ligand binding on toll-like and cytokine 
receptors, initiating the release of calcium into the cytoplasm by the endoplasmic reticulum (14). 
The shift in cytoplasmic calcium concentration causes NADPH oxidase-complexes to generate 
reactive oxygen species (ROS) (15) which in turn causes granular and nuclear membranes to lyse 
(14). The cytoplasmic enzymes neutrophil elastase and myeloperoxidase enter the nuclear area 
and work to decondense chromatin and deiminate nuclear histones (14, 16). Peptidyl arginine 
deiminase 4 (PAD4) citrullinates arginine and removes the positive charge of nuclear proteins, 
allowing neutrophil elastase and myeloperoxidase to decondense chromatin and deiminate 
chromatin-bound histones (17). Once chromatin decondenses, it is expelled out of the nucleus, 
into the extracellular space, and forms a large web with antimicrobial properties. This web is the 
neutrophil extracellular DNA trap, NET.
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NET-Associated Cytokines and Biomarkers 
 
Granulocyte-Colony Stimulating Factor 
 
Granulocyte-colony stimulating factor (G-CSF) is a glycoprotein that stimulates the 
production, proliferation, and differentiation of neutrophils and increases NETosis (18). 
Circulating G-CSF increases during injury and infection as the body attempts to produce more 
antimicrobial and immune regulating neutrophils. Data show that circulating histone-complexed 
DNA and myeloperoxidase increase within one hour following injection of G-CSF, suggesting 
that increased NETosis occurs rapidly with G-CSF elevation (18). Demers et al. found that 
certain tumor types secrete G-CSF which ‘primes’ neturophils to enter NETosis (19). In mouse 







Interleukin-6 (IL-6) is both a pro-inflammatory and anti-inflammatory cytokine produced by T 
cells and macrophages and helps to activate the complement system of the innate immune 
response (20). The complement system works to enhance antibodies and immune cell function 
during infection or injury. IL-6 also helps to stimulate neutrophil production in bone marrow 
during the inflammatory cascade (21). Studies of lung tissue damage found that in vitro NET 
formation stimulated alveolar epithelial cells to secrete a significantly higher amount of IL-6 
compared to neutrophils that had undergone forced necrosis, indicating that IL-6 is directly 
increased by NETosis (22).
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High Sensitivity C-Reactive Protein 
 
High sensitivity CRP (hs-CRP) is a measure of both chronic and acute phase inflammation and 
increases in response to an increase in IL-6. Due to the mechanistic relationship between hs-CRP 
and IL-6, hs-CRP is used as a risk indicator by proxy in many inflammatory conditions (20). 
This biomarker rapidly shifts in response to multiple forms of stress, so its clinical use is global 




Mechanism of NETs in Cancer Recurrence 
 
Recent data associate NET formation in the presence of cancer with trapping circulating 
tumor cells leading to subsequent metastasis in nearby tissue (5, 8). Tumor resection and partial 
or whole organ removal are common cancer treatments, yet metastasis is observed in many 
patients with operation-induced inflammation or infection (3, 8). Neutrophils eject DNA webs 
into the areas surrounding inflamed and infected tissue in an effort to protect the body, but recent 
data suggest that this action of building NETs may be harmful in the presence of cancer (5, 7, 8). 
Cools-Lartigue et al. observed cancer cell ‘trapping’ in NET formations and found that this 
action contributed to liver metastases in the presence of infection (8). The NETs that ‘trap’ these 
 
circulating cancer cells are located in different areas of the body and therefore increase linkage 
of cancer cells to previously healthy tissues (8). Huh et al. observed that circulating melanoma 
cells become stuck in the deep capillaries of the lung and secrete inflammatory cytokines, which 
recruits neutrophils (7). These mobilized neutrophils build NETs that allow the melanoma cells 
to anchor themselves to lung tissue (7). NETs have multiple mechanisms through which they 
help cancer cells both invade healthy tissue and proliferate.
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In addition to their contribution to metastasis, NETs have attached protein complexes that 
release protease enzymes that have been found to speed the rate of cancer cell proliferation in 
murine models (4, 5, 23). Li et al. found that when instigating NET formation in the lungs of 
mice, proliferation of injected cancer cells was increased and metastasis occurred at a 
significantly faster rate (23). In this same study, two NET enzymes were identified as being 
involved in this metastasis: neutrophil elastase and matrix metalloproteinase 9 (23). These 
proteases can be used as a plasma marker for NET presence and volume. Multiple studies have 
demonstrated the use of DNAse, an enzyme that cleaves linkages in the DNA structure, for the 
inhibition of NET formation. These studies found a reduction of cancer proliferation and 
migration (5, 8, 23), directly implicating the protease activity and ‘trapping’ behavior of NETs 
with cancer invasion and metastasis. The use of DNAse as a post-operative cancer therapy is an 
area that should be further researched due to limited understanding of how the DNAse treatment 
would impact transcriptive processes long-term (23). Though this method of prevention is not 





Measuring neutrophils as a prognostic tool 
 
Measurements of neutrophil volume are used as a prognostic tool, but it is unknown 
whether increased neutrophil volume is associated with NET levels. Kawahara et al. found that a 
neutrophil-to-lymphocyte ratio (NLR) measured through a simple and cost-effective complete 
blood count panel was a useful indicator of overall patient survival following RC (24). The 
cancer recurrence rate was significantly higher for those with a higher NLR >2.38 (24). This 
impact was even greater when hs-CRP measures were high, further building the relationship
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between neutrophil mobilization and inflammation (24). Tao et al. utilized this type of NLR as a 
prognostic tool in pancreatic ductal adenocarcinoma and found it to be effective in predicting 
post-operative metastasis (6). Use of a NLR as an indicator of post-operative risk has been used 
with effectiveness (24, 25), which may also implicate NETs in the mechanism of metastasis. In a 
previous analysis of this data set, Hamilton-Reeves et al. found that individuals supplemented 
with the specialized immunonutrition (SIM) beverage had a lower postoperative NLR than those 
in the control (10). The possible association between NETs and inflammation not only identifies 
poor prognosis on overall patient health, but it may also indicate increased risk of metastasis and 
morbidity (8, 24). SIM has shown the potential to lower NLR, but the effect of SIM on plasma 






Bladder cancer is a common cancer with a gold standard treatment that does not prevent 
recurrence (1). Through improved understanding of cancer proliferation and migration, survival 
rates can be significantly increased. The immune system may be used by cancer for its own 
advantage and NET formation may be a contributor to this process. Immune system response to 
infection and surgical stress causes acute inflammation and NET formation (5-8, 24), which may 
increase the risk of post-operative infection and cancer recurrence. Using the NLR and plasma 
NETs as biomarkers (8, 24) perioperatively may help to identify those at greatest risk and who 
may benefit from treatments such as DNAse therapy, PAD4 inhibitors, or SIM therapy (5, 23). 
Optimizing nutrition interventions to improve the response to surgery may offer an affordable, 
complementary approach to cancer treatment in those receiving RC.
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CHAPTER 3: Methods 
 
I. Overview and Design 
 
Data were obtained from a pilot randomized clinical trial designed to compare immune 
response and clinical outcomes after cystectomy between standard oral nutrition support (Nestlé 
Boost Plus©) and SIM (Nestlé Impact Advanced Recovery©) (10, 26). Twenty-nine men 
scheduled to undergo RC were recruited within the Kansas Health System (KHS). Permuted 
block randomization was used to assign study arm. All participants received standard of care and 
consumed nutrition supplementations three times a day for 5 days before and 5 days after RC 
surgery. Blood samples were collected at baseline before surgery or supplementation, 3 hours 






The population included 29 men diagnosed with primary bladder cancer with no existing 
metastasis. Patients were referred from the KHS by multiple urologic oncologists. Exclusion 
criteria included patients with unintentional weight loss ≥10% in the previous 6 months, a BMI 
≤18.5% kg/m2, bladder cancer that is not urothelial in nature, active infections, difficulty 
 
swallowing or those with potential for aspiration, those unable to tolerate oral intake, those with 
a history of gout and gout-related arthritis, those with a history of uric acid kidney stones, and 




III. Ethical Approval 
 
Participants voluntarily entered this study. The study was approved by the Human 
 
Subjects Committee and Institutional Review Board at the University of Kansas Medical Center.
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All participants provided informed consent according to institutional guidelines and 
acknowledged that blood samples would be analyzed for future research questions. The database 
was stored within Research Electronic Data Capture (REDCap) accessible only through a secure 
server. The University of Kansas Medical Center is a Health Insurance Portability and 
Accountability Act (HIPAA)-covered entity and complies with all HIPAA regulations regarding 
data privacy and security.  Access to study data is password protected; individual identifiers 







Stored plasma samples collected from ONS and SIM participants at baseline, intra- 
operative, and POD 2, 14, and 30 were analyzed for NET formation (elevated >0.2 OD). A 
sandwich enzyme-linked immunosorbent assay (ELISA) developed and provided by the Egeblad 
laboratory was used to measure neutrophil elastase that is associated with NET formation (27). 
This method was developed and validated as a proxy for NETs in human samples from patients 
with chronic disease and healthy controls (28-31). This assay is specific to human neutrophil 
elastase through its use of a horseradish peroxidase-linked polyclonal antibody and this method 





We measured plasma cytokines that are associated with recruitment of neutrophils to 
inflammatory or infected tissues and subsequent NET formation. Granulocyte-colony stimulating 
factor (G-CSF) and plasma IL-6 were measured using MILLIPLEX® map human cytokine kit 1 
(Millipore, Billerica, MA, USA) with a standard curve range of 3.2-10,000 pg/ml. High-sensitivity C- 
reactive protein (hs-CRP) was measured in serum by Quest Diagnostics Laboratories (Lenexa,
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KS) with a detection range of 1.0-10.0 mg/L. All cytokines were measured at the University of 
 





V. Statistical Analysis 
 
Statistical analysis of differences between plasma markers in patients supplemented with 
SIM and ONS were calculated using the generalized linear mixed method of analysis using SAS. 
NET formation between groups and 30-day infection rate and 3-year cancer recurrence were 
calculated with generalized linear mixed models using GLIMMIX via SAS. A significance level 
of p<0.05 was set as statistically significant. Spearman’s correlation tests were used to 
investigate NET formation and IL-6 and G-CSF with R version 3.3.3 (32). Statistical analyses 








Twenty-nine study participants were randomized into the SIM (n=14) and ONS (n=15) 
groups. Group characteristics were similar for age, clinical staging, smoking status, Charlson 
Comorbidity Index score, urinary diversion type, PG-SGA score, and neoadjuvant chemotherapy 
treatment. Body mass index (BMI) differed between the groups (+3.6 kg/m2  ONS, p=0.004). 
Complications with obtaining blood samples and participant inability to attend follow-up visits 
limits data at all time points. There were 7 (50%) participants from SIM and 2 (13.3%) from 
ONS that had enough plasma from all five time points for analyses. NETs were detectable in the 







Table 1- Minimum and maximum NET levels over time 
 
 
Minimum             Maximum 
 
Baseline (n=29)             0.045                     0.426 
 
Surgery (n=28)              0.117                     1.181 
 
POD2 (n=23)                0.115                     0.538 
 
POD14 (n=13)              0.118                     0.761 
 
POD30 (n=19)              0.098                     0.717 
 
1NET formation measured in optical density (OD) 
2Seven SIM and 2 ONS participants were analyzed at all 5 points
15  
There was no significant difference in NETs between those with clinically identified 
infection and those without infection (p=0.647). NETs trended higher at POD 30 compared to 
baseline when all participants were evaluated together, although this trend was not statistically 





Figure 1- NETs (OD, left) and infection (No, Yes)
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There was no significant difference in NETs between those who had cancer recurrence 
within three years following RC and those who did not recur (p=0.258). Regardless of participant 






Figure 2- NETs (OD, left) and 3-year cancer recurrence (Yes, No)
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NET formation was not statistically different between the SIM and ONS throughout the 
intervention. There was an observed shift of mean NET formation between groups from the 
intraoperative time point to POD2. At POD2, the largest difference in NET formation between 








Table 2- Mean NET formation between groups over time 
 
 
SIM                        ONS 
 
Baseline                           0.225                      0.262 
 
Intraoperative                  0.246                      0.272 
 
POD2                               0.345                      0.242 
 
POD14                             0.298                      0.290 
 




G-CSF was significantly different between SIM and ONS from baseline to POD2 
(p=0.0096). G-CSF was significantly different between SIM and ONS from the intraoperative 



















G-CSF showed an inverse relationship with NET formation in both groups with lower 
plasma levels during periods of higher detectable NETs. There was a weak relationship between 
G-CSF and NETs at POD2 in the entire cohort (r= 0.142). However, there was no statistically 




Figure 4- NETs (OD, left, red) and G-CSF (pg/ml, right, black) over time in SIM 




Figure 5- NETs (OD, left, red) and G-CSF (pg/ml, right, black) over time in ONS 




Correlational analyses identified a weak inverse relationship between IL-6 and NETs at 
the intraoperative time point (r= -0.153) and POD2 (r= -0.129). There was no significant 
relationship identified between IL-6 and NETs, though there appeared to be a tighter relationship 
in SIM versus ONS (Figure 6, Figure 7). There was no statistically significant correlation 






Figure 6- NETs (OD, left, red) and plasma IL-6 (pg/ml, right, black) over time in 




Figure 7- NETs (OD, left, red) and plasma IL-6 (pg/ml, right, black) over time in 








Figure 8- NETs (OD, left, red) and hs-CRP (mg/L, right, black) over time in SIM 






Figure 9- NETs (OD, left, red) and hs-CRP (mg/L, right, black) over time in the 






CHAPTER 5: Discussion 
 
This study investigated whether NET measurement is feasible in individuals with muscle- 
invasive bladder cancer before, during, and after RC. We also examined to see if SIM modulated 
NET formation. NETs were present in all plasma samples provided. There were no significant 
differences between NET level by clinically identified infections or 3-year cancer recurrences. 





This is the first clinical investigation of NETs in bladder cancer patients undergoing RC. 
Our data suggest that NETs are detectable in the perioperative window of RC. NETs were
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detectable in every participant sample at all time points. Difficulty with blood draws and 
participants’ inability to attend follow-up visits account for the lower number of samples than 
patients at all time points. The process of NETosis takes approximately 4 to 6 hours and NETs 
have an observed lifespan of 6 to 8 hours in human blood (33). NETs can be observed in tissue 
samples for up to 7 days following infection or tissue injury (33). Our findings align with studies 
in other cancer types regarding the presence of NETs in patient plasma (5-7). Due to the novelty 
of NET research, there is no defined reference range and there is no established ceiling measure. 
Biomarkers and measures of NETs are highly variable across individuals and disease states, 
therefore it cannot be determined if our cohort was unique in NET levels. We observed multiple 
outliers that shifted mean values. Due to the lack of a reference range or ceiling measure, these 





Individuals who undergo RC are at high risk of developing a post-operative infection (4) 
and cancer recurrence (3). Our data contribute to a large body of research aimed to improve post- 
operative outcomes by investigating whether NETs following surgical stress or infection 
promote recurrence. Previous research has shown that NETs trap circulating tumor cells (5, 8), 
promote metastasis (5, 8, 23), and increase proliferation of cancer cells (4, 5, 23), but we 
observed no difference in NET levels perioperatively in those who recurred and those who did 
not. There also was no statistically significant difference in NETs between those participants 
who developed an infection within 30 days post-operatively and those who did not. Therefore, 
the highly variable data from this small cohort did not establish a correlation between NETs, 
infection, and early recurrence.
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Hamilton-Reeves et al. found that SIM had significantly lower IL-6 from intraoperative 
point to POD2 (p= 0.022) and that mean IL-6 was 42.8% lower (p=0.020) in the SIM group than 
ONS at POD2 (26). Overall, there was no significant relationship between IL-6 and NETs, 
suggesting that the reduction in IL-6 was related to other mechanisms. The hypothesized 
relationship between IL-6 and NET formation is better demonstrated in the SIM group, however 
data points in the ONS group are too variable to draw conclusions. A study with more frequent 
blood draws may better evaluate the associations between cytokine and NETs levels. Hamilton- 
Reeves et al. found no significant difference in hs-CRP between groups (p= 0.908) (26) and hs- 




There was a significant difference in G-CSF between SIM and ONS from baseline to 
POD2 and from surgery to POD2. G-CSF was only weakly correlated with NETs at POD2, 
suggesting that differences in G-CSF between groups may serve functions other than 
upregulating NETosis. G-CSF is provided as both a prophylactic and therapeutic treatment in 
immunosuppressed individuals (18) to stimulate leukocyte production and bolster immune 
function. Perioperative SIM reduced post-operative infection in this cohort (10, 26) and we 
observed a significantly higher amount of G-CSF in SIM at the intraoperative time point. ONS 
had significantly higher G-CSF at POD2. This suggests that the nutrients provided through our 
immunonutrition drink better prepared intervention participants to fight infection through a faster 
immune system response. Though G-CSF was not associated with NET levels, future studies 
should continue to use G-CSF as an immune system biomarker.
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We observed no difference in NET levels between participants receiving SIM or ONS, 
suggesting that this specific SIM drink does not modulate NET formation. Previous analyses of 
these data found that individuals receiving SIM had fewer infections following RC than those 
receiving ONS (10, 26). It was previously inferred that arginine-enriched SIM modulates 
immune system function following surgery by preventing T cell suppression and reduced 
lymphocyte proliferation through arginine repletion (10, 26). A critical step in NETosis is the 
deimination of arginine into citrulline by PAD4, therefore it can be hypothesized that 
supplementation with arginine may promote NET formation. However, we observed no 
difference in NETs between those receiving arginine-enhanced SIM and ONS. Our findings 
therefore may indicate arginine is triaged and used for bolstered proliferation of macrophages, 





While NETs are detectable in the plasma of surgical oncology patients undergoing RC, 
our findings suggest NETs are quite variable and are not tightly associated with clinical 
outcomes. Further, NETs were not modified by a specialized immunonutrition intervention, 
therefore the improved outcomes observed in this cohort may be attributed to other mechanisms 
such as arginine repletion, anti-inflammatory omega-3 fatty acid supplementation, early post- 
operative feeding, and improved nutrition status which are all currently being explored in a large 
phase III randomized controlled trial
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We were the first to look at NET formation following RC and modulation through a 
specialized immunonutrition intervention, but this novel study has its limitations. Primarily, this 
was a small cohort treated at a single-site for a brief period of time. RC has a long-lasting impact 
on the body and immune system. SIM may have a greater impact on NETs over a longer period 
and modulation of this immune function could have benefits. Findings from other research that 
identified NETs as cancer-promoting were in other cancer types (5-8). Muscle-invasive bladder 
cancer is severe and has poor prognostic outcomes; therefore a study measuring one mechanism 




There was a lack of heterogeneity in this study cohort. All participants were male and 
predominantly white (93%). This cohort was not representative in that 85% of participants 
formerly or currently smoked. Of that 85%, 17% were current smokers. This is not representative 
of the national average and therefore may have skewed the results. Further, it is widely known 
that smoking tobacco is associated with primary lung cancer, secondary metastases, and other 
co-morbidities such as cardiovascular disease, COPD, and type II diabetes. It is difficult to limit 
confounding factors that may influence NET formation, immune system dysregulation, and the 




Analyses of NETs was run on banked plasma samples through an off-site laboratory. The 
length of time in formation and limited lifespan of NETs make measures highly variable based 
on the time of the blood draw (33). NETs are fragile structures that are easily destroyed through
27  
various methods of observation and handling of samples (35), therefore storage and shipment of 
plasma to an off-site, out-of-state laboratory may have affected our findings. Analyses on banked 






This was the first randomized clinical trial to investigate the feasibility of detecting NETs 
before, during, and after RC, whether NETs are associated with infection and cancer recurrence, 
and whether SIM can modulate NETs. The gold standard treatment for this cancer does not 
prevent recurrence and has severe complications. Contributing novel data to the growing body of 




NETs were detectable in all obtained samples. Due to the limited research on NETs, there 
is no standardized methodology. We utilized a widely accepted method for measurement and 
were able to detect NETs in all samples. Larger samples in future studies will perhaps provide 







Though our findings were null, these data provide a valuable contribution to research. We 
found that NET formation is detectable in the plasma of surgical oncology patients, but that 
measuring NETs was not a useful biomarker or target for improved outcomes. RC patients have 
a high rate of post-operative infection and cancer recurrence, but we did not find an association 
between NET formation on either outcome. NETosis and microbe trapping is a fundamental part
28  
of the innate immune system that is poorly understood. Future research should be aimed at larger 
study samples with greater heterogeneity. As our understanding of NETs grows, specialized 
immunonutrition could be optimized to modulate identified pathways. A larger, multi-center 






Immune system regulation through improved perioperative nutrition was shown to 
 
benefit this population (10, 26). The SIM drink provided during this intervention improved post- 
operative infection through mechanisms other than modulating NETosis. NETs were similar 
between groups at all time points and were not implicated in post-operative infection or in those 
with cancer recurrence. Specialized immunonutrition has been identified as a low-cost, high- 
impact way of improving outcomes in surgical oncology patients. We will continue to investigate 
the mechanisms through which immunonutrition modulates inflammation and the immune 
system. Neutrophil extracellular DNA traps are at the forefront of immunological research in 
many disease states and our research provides further insight into whether NETs are feasible to 
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